Statin use in low-income and middle-income countries.

Lancet Glob Health

Department of Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany; Hypertension Center, University Hospital of Cologne, Cologne, Germany.

Published: July 2022

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2214-109X(22)00219-4DOI Listing

Publication Analysis

Top Keywords

statin low-income
4
low-income middle-income
4
middle-income countries
4
statin
1
middle-income
1
countries
1

Similar Publications

Objectives: The main objective was to evaluate the cost-effectiveness of various medical therapy combinations in managing chronic coronary syndrome (CCS) in Iran, based on real-world and patient-level data.

Design: A cost-utility analysis employing a Markov model was conducted using data from a retrospective cohort study.

Setting: The study was conducted in the healthcare setting of Iran, focusing on primary and secondary care.

View Article and Find Full Text PDF

Importance: The Southern Community Cohort Study (SCCS) Polypill Trial showed that a cardiovascular polypill (a single pill containing a statin and 3 half-standard dose antihypertensive medications) effectively controls cardiovascular disease (CVD) risk factors in a majority Black race and low-income population. The cost-effectiveness of polypill treatment in this population has not been previously studied.

Objective: To determine the cost-effectiveness of the cardiovascular polypill.

View Article and Find Full Text PDF

Background: Ischemic heart disease is a leading cause of death globally with a disproportionate burden in low- and middle-income countries (LMICs). Natural language processing (NLP) allows for data enrichment in large datasets to facilitate key clinical research. We used NLP to assess gender differences in symptoms and management of patients hospitalized with acute myocardial infarction (AMI) at Aga Khan University Hospital-Pakistan.

View Article and Find Full Text PDF

Background: Patients with a history of coronary revascularization are at a higher risk for subsequent cardiovascular events and all-cause mortality. Lowering LDL-cholesterol (LDL-C) levels post-revascularization significantly reduces these risks.

Methods: This analysis compared LDL-C-lowering therapies at baseline and over time among patients with and without prior coronary revascularization in the GOULD registry (a prospective multicenter cohort study).

View Article and Find Full Text PDF

In low- and middle-income countries where the majority of preventable cardiovascular disease deaths occur, less than 10% of eligible patients receive statins for primary cardiovascular disease prevention. Since 2017, the Global Hearts initiative has implemented simple World Health Organization (WHO) HEARTS hypertension and diabetes treatment protocols. In this editorial, we propose an approach of integrating statin treatment into existing HEARTS hypertension and diabetes protocols as a way of expanding statin coverage in low-and middle-income countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!